As we continue to advance in our understanding and treatment capabilities, our response to uncontrolled AD and PN becomes more effective, paving the way for a future where patients can lead healthier, more comfortable lives8.
What are the hidden challenges of living with uncontrolled Atopic Dermatitis (AD) and Prurigo Nodularis (PN)?
Explore the distinct clinical manifestations of Atopic Dermatitis (AD) and Prurigo Nodularis (PN), their impact on patients' lives, and the common thread of type 2 inflammation. Understand how these chronic skin conditions differ and intersect in this comprehensive overview.
A recent study led by professor Jonathan Silverberg involving over 30,000 participants has highlighted the significant psychosocial burden faced by adults with early-onset atopic dermatitis (AD). Learn more and continue reading.
Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.
Du är på väg att lämna campus.sanofi/se Sanofi ansvarar inte för innehållet på denna externa webbplats.
Den här webbplatsen innhåller information som endast är riktad till sjukvårdspersonal. Vänligen bekräfta nedan för att ta del av information, filmer, podcast och övrigt material.